Nystatin LF Aronex/Abbott

Current Opinion in Investigational Drugs

Volumn 2, Issue 4, 2001, Pages 488-495

  Arikan, S ^a   Rex, J H ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN; AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ERGOSTEROL; FLUCONAZOLE; ITRACONAZOLE; NYSTATIN;

ANTIBIOTIC RESISTANCE; ANTIFUNGAL ACTIVITY; ASPERGILLOSIS; CANDIDA ALBICANS; CHILL; CLINICAL TRIAL; DOSE RESPONSE; DRUG BINDING; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG FORMULATION; DRUG INTOXICATION; DRUG METABOLISM; DRUG SYNTHESIS; EXPERIMENTAL MODEL; FUNGAL MENINGITIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LICENSING; NONHUMAN; RASH; RESPIRATORY DISTRESS; REVIEW; STRUCTURE ACTIVITY RELATION; SYSTEMIC MYCOSIS;

ANTIBIOTICS, ANTIFUNGAL; CLINICAL TRIALS; DRUG CARRIERS; HUMANS; LIPOSOMES; NYSTATIN; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0035043264     PISSN: 09678298     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (63)

1. Formulation, toxicity and antifungal activity in vitro of liposome-encapsulated nystatin as therapeutic agent for systemic candidiasis
2. Toxicity and therapeutic effects in mice of liposome-encapsulated nystatin for systemic fungal infections
3. Pharmacokinetics of liposomal nystatin in patients with human immunodeficiency virus infection
4. Annual report - Argus Pharmaceuticals - 1994
5. Aronex Pharmaceuticals Inc (company brochure)
6. Phase I study of maximum tolerated dose of intravenous liposomal nystatin for the treatment of refractory febrile neutropenia (RFN) in patients with hematological malignancies
7. Aronex announces the start of phase III trial of Nystatin LF
8. Aronex Pharmaceutical Inc initiates phase III clinical study of Nystatin (LF)
9. Aronex Pharmaceuticals Inc. reports first quarter 1997 results
10. Aronex Pharmaceuticals Inc provides clinical development update for Nyotran (TM)
11. Aronex/Ferrer signs European agreement with Nyotran
12. Aronex presents results for antifungal agent Nyotran at ICAAC conference. Nyotran exhibits activity against resistant fungal organisms
13. Aronex Pharmaceuticals seeks European approval in Spain for Nyotran antifungal product
14. Aronex Pharmaceuticals reports data on Nyotran antifungal agent at European Congress of Medical Mycology. Nyotran exhibits differentiating antifungal activity in over 500 samples in multiple in vitro studies
15. Evaluation of antifungal activity of nyotran against various pathogenic fungi
16. Aronex Pharmaceuticals presents results for antifungal agent Nyotran at American Society for Microbiology Conference; Nyotran exhibits strong fungicidal profile in resistant strains
17. Aronex Pharmaceuticals presents at BIO'98 Investor & Partnering Conference
18. Aronex Pharmaceuticals and Abbott Laboratories enter agreement to commercialize Nyotran worldwide
19. Aronex Pharmaceuticals receives milestone payments for antifungal agent Nyotran
20. Aronex Pharmaceuticals reports data on Nyotran antifungal agent at European Congress of Clinical Microbiology and Infectious Disease. Nyotran exhibits differentiating antifungal activity
21. Aronex Pharmaceuticals receives milestone payment for late-stage antifungal agent Nyotran
22. In vitro antifungal activity of Nyotran (liposomal nystatin) against opportunistic filamentous fungi
23. Aronex Pharmaceuticals Inc reports second quarter 1999 results - ODAC meeting for Atragen confirmed for September 1999 - Patient enrollment completed in Nyotran cryptococcal meningitis phase III trial
24. Benefit shown, Aronex plans NDA of Nyotran
25. Liposomal nystatin (Nyotran) vs. amphotericin B (Fungizone) in empiric treatment of presumed fungal infection in neutropenic patients
26. Multicenter study to evaluate the safety and efficacy of various doses of liposome-encapsulated nystatin in non-neutropenin patients with candidemia
27. Aronex Pharmaceuticals Inc reports third quarter 1999 results
28. Aronex Pharmaceuticals announces preliminary results of a phase III clinical trial for Nyotran
29. EORTC-IFCG phase II study on liposomal nystatin in patients with invasive Aspergillus (IA) infections, refractory or intolerant to conventional/lipid ampho B (AB)
30. Efficacy of Nyotran (liposomal nystatin) in the treatment of disseminated candidiasis in a neutropenic guinea pig model
31. Aronex Pharmaceuticals and Abbott Laboratories enter agreement to commercialize Nyotran worldwide
32. In vitro antifungal activity of nyotran (liposomal nystatin) against opportunistic filamentous fungi
33. Aronex Pharmaceuticals Inc reports second quarter 1999 results - ODAC meeting for Atragen confirmed for September 1999 - Patient enrollment completed in Nyotran cryptococcal meningitis phase III trial
34. Aronex Pharmaceuticals reports phase II data on Nyotran in patients with invasive aspergillus infections
35. Aronex Pharmaceuticals Inc reports third quarter 2000 results
36. Drug therapy reviews: Clinical pharmacology and therapeutic use of antimycotic drugs
37. Fluconazole versus nystatin in the treatment of oral candidosis
38. Treatment of deep mycoses
39. New antifungal agents and preparations
40. High-performance liquid chromatographic determination of liposomal nystatin in plasma and tissues for pharmacokinetic and tissues for pharmacokinetic and tissue distribution studies
41. Antifungal activity of isomeric forms of nystatin (NYS)
42. In vitro activity of a new liposomal nystatin formulation against opportunistic fungal pathogens
43. In vitro antifungal activity of liposomal nystatin in comparison with nystatin, amphotericin B cholesteryl sulfate, liposomal amphotericin B, amphotericin B lipid complex, amphotericin B desoxycholate, fluconazole and itraconazole
44. In vitro activity of liposomal nystatin compared with amphotericin B and fluconazole against clinical Candida isolates
45. Comparison of in vitro antifungal activities of free and liposome-encapsulated nystatin with those of four amphotericin B formulations
46. Comparison of in vitro activity of liposomal nystatin against Aspergillus species with those of nystatin, amphotericin B (AB) deoxycholate, AB colloidal dispersion, liposomal AB, AB lipid complex, and itraconazole
47. In vitro susceptibility of Candida dubliniensis to current and new antifungal agents
48. Activity of liposomal nystatin against disseminated Aspergillus fumigatus infection in neutropenic mice
49. Liposomal nystatin against experimental pulmonary aspergillosis in persistently neutropenic rabbits: Efficacy, safety and non-compartmental pharmacokinetics
50. Dose range evaluation of liposomal nystatin and comparisons with amphotericin B and amphotericin B lipid complex in temporarily neutropenic mice infected with an isolate of Aspergillus fumigatus with reduced susceptibility to amphotericin B
51. Safety and efficacy of multilamellar liposomal nystatin against disseminated candidiasis in persistently neutropenic rabbits
52. Compartmental pharmacokinetics and tissue distribution of multilamellar liposomal nystatin in rabbits
53. Comparative murine pharmacokinetics of polyene antifungal agents
54. Plasma lipoprotein distribution of liposomal nystatin is influenced by protein content of high-density lipoproteins
55. Diversity of lipid-based polyene formulations and their behavior in biological systems
56. Species differences in the proportion of plasma lipoprotein lipid carried by high-density lipoproteins influence the distribution of free and liposomal nystatin in human, dog, and rat plasma
57. Polyene antibiotics: Relative degrees of in vitro cytotoxicity and potential effects on tubule phospholipid and ceramide content
58. The reproductive and developmental toxicity of the antifungal drug Nyotran (liposomal nystatin) in rats and rabbits
59. Treatment of refractory episodes of candidemia in non-neutropenic patients with liposomal nystatin (Nyotran)
60. New agents for treatment of systemic fungal infections
61. In vitro antifungal activity of Nyotran (liposomal nystatin) versus four formulations of amphotericin B, fluconazole and itraconazole against cryptococcus neoformans clinical isolates
62. MIC comparisons of six polyene preparations in vitro
63. In vitro antifungal activity of nyotran against clinical isolates